Ryohei Yamamoto

Dr. Ryohei Yamamoto

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RYRyohei Yamamoto
Ryohei Yamamoto
SOSatoru Robert Okazaki
Satoru Robert Okazaki
YFYoshihito Fujita
Yoshihito Fujita
NSNozomu Seki
Nozomu Seki
YKYoshufumi Kokei
Yoshufumi Kokei
CNChihiro Narita
Chihiro Narita
The effects of lower tidal volume ventilation (LTV) were controversial for patients with acute respiratory distress syndrome (ARDS). This systematic review and meta-analysis aimed to evaluate the use of LTV strategy in patients with ARDS. We performed a literature search on MEDLINE, CENTRAL, EMBASE, CINAHL, “Igaku-Chuo-Zasshi”, clinical trial registration sites, and the reference of recent guidelines. We included randomized controlled trials (RCTs) to compare the LTV strategy with the higher tidal volume ventilation (HTV) strategy in patients with ARDS. Two authors independently evaluated the eligibility of studies and extracted the data. The primary outcomes were 28-day mortality. We used the GRADE methodology to assess the certainty of evidence. Among the 19,864 records screened, 13 RCTs that recruited 1874 patients were included in our meta-analysis. When comparing LTV (4–8 ml/kg) versus HTV (> 8 ml/kg), the pooled risk ratio for 28-day mortality was 0.79 (11 studies, 95% confidence interval [CI] 0.66–0.94, I2 = 43%, n = 1795, moderate certainty of evidence). Subgroup-analysis by combined high positive end-expiratory pressure with LTV showed interaction (P = 0.01). Our study indicated that ventilation with LTV was associated with reduced risk of mortality in patients with ARDS when compared with HTV.Trial registration: UMIN-CTR (UMIN000041071).

15 February 2024 in Journal of Intensive Care
Verified
Journal Article
Open access
PDF file
HOHiromu Okano
Hiromu Okano
RYRyohei Yamamoto
Ryohei Yamamoto
YIYudai Iwasaki
Yudai Iwasaki
DIDaisuke Irimada
Daisuke Irimada
DKDaisuke Konno
Daisuke Konno
MYMasanori Yamauchi
Masanori Yamauchi
Background: The HACOR score for predicting treatment failure includes vital signs and acid–base balance factors, whereas the ROX index only considers the respiratory rate, oxygen saturation, and fraction of inspired oxygen (FiO2). We aimed to externally validate the HACOR score and ROX index for predicting treatment failure in patients with coronavirus disease 2019 (COVID-19) on high-flow nasal cannula (HFNC) therapy in Japan. Methods: This retrospective, observational, multicenter study included patients, aged ≥ 18 years, diagnosed with COVID-19 and treated with HFNC therapy between January 16, 2020, and March 31, 2022. The HACOR score and ROX index were calculated at 2, 6, 12, 24, and 48 h after stating HFNC therapy. The primary outcome was treatment failure (requirement for intubation or occurrence of death within 7 days). We calculated the area under the receiver operating characteristic curve (AUROC) and assessed the diagnostic performance of these indicators. The 2-h time-point prediction was considered the primary analysis and that of other time-points as the secondary analysis. We also assessed 2-h time-point sensitivity and specificity using previously reported cutoff values (HACOR score > 5, ROX index < 2.85). Results: We analyzed 300 patients from 9 institutions (median age, 60 years; median SpO2/FiO2 ratio at the start of HFNC therapy, 121). Within 7 days of HFNC therapy, treatment failure occurred in 127 (42%) patients. The HACOR score and ROX index at the 2-h time-point exhibited AUROC discrimination values of 0.63 and 0.57 (P = 0.24), respectively. These values varied with temporal changes—0.58 and 0.62 at 6 h, 0.70 and 0.68 at 12 h, 0.68 and 0.69 at 24 h, and 0.75 and 0.75 at 48 h, respectively. The 2-h time-point sensitivity and specificity were 18% and 91% for the HACOR score, respectively, and 3% and 100% for the ROX index, respectively. Visual calibration assessment revealed well calibrated HACOR score, but not ROX index. Conclusions: In COVID-19 patients receiving HFNC therapy in Japan, the predictive performance of the HACOR score and ROX index at the 2-h time-point may be inadequate. Furthermore, clinicians should be mindful of time-point scores owing to the variation of the models’ predictive performance with the time-point. Trial registration UMIN (registration number: UMIN000050024, January 13, 2023)

13 February 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RYRyohei Yamamoto
Ryohei Yamamoto
HYHajime Yamazaki
Hajime Yamazaki
SYShungo Yamamoto
Shungo Yamamoto
YUYuna Ueta
Yuna Ueta
RURyo Ueno
Ryo Ueno
YYYosuke Yamamoto
Yosuke Yamamoto
Background: Previous studies have shown that diarrhea, defined as a dichotomized cutoff, is associated with increased mortality of patients in intensive care units (ICUs). This study aimed to examine the dose-response relationship between the quantity of diarrhea and mortality in ICU patients with newly developed diarrhea. Methods: We conducted this single-center retrospective cohort study. We consecutively included all adult patients with newly developed diarrhea in the ICU between January 2017 and December 2018. Newly developed diarrhea was defined according to the World Health Organization definition. The consistency of diarrhea was evaluated by the Bristol stool chart scale, and the quantity of diarrhea was assessed on the day when patients newly developed diarrhea. The primary outcome was in-hospital mortality. The risk ratio (RR) and 95% confidence interval (CI) for the association between diarrhea quantity and mortality were estimated using multivariable modified Poisson regression models. Results: Among the 231 participants, 68.4% were men; the median age was 72 years. The median diarrhea quantity was 401g (interquartile range [IQR] 230‒645g), and in-hospital mortality was 22.9%. More diarrhea at baseline was associated with higher in-hospital mortality; the adjusted RR (95% CI) per 200-g increase was 1.10 (1.01‒1.20), p = 0.029. In sensitivity analyses with near quartile categories of diarrhea quantity (<250g, 250–399g, 400–649g, ≥650g), the adjusted RRs for each respective category were 1.00 (reference), 1.02 (0.51–2.04), 1.29 (0.69–2.43), and 1.77 (0.99–3.21), p for trend = 0.033. Conclusions: A greater quantity of diarrhea was an independent risk factor for in-hospital mortality. The diarrhea quantity may be an indicator of disease severity in ICU patients.

17 November 2021 in IDCases
Verified
Journal Article
Open access
SISatoshi Ide
Satoshi Ide
SSSho Saito
Sho Saito
TATsubasa Akazawa
Tsubasa Akazawa
TFTakahito Furuya
Takahito Furuya
JMJunichi Masuda
Junichi Masuda
NONorio Ohmagari
Norio Ohmagari
Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old American man who underwent mechanical ventilation and ECMO for severe COVID-19 was administered remdesivir for ten days. The loading dosage was 200 mg at 7 PM on day 12 and 100 mg daily at 0:00 PM from day 13–21, administered within 1 h. The pharmacokinetic analysis was performed. The serum creatinine concentration was within the normal range of 0.5–0.7 mg/dL during treatment. According to the pharmacokinetic analysis, the plasma concentrations of remdesivir and GS-441524 4 h after administration (C4) were 662 ng/mL and 58 ng/mL, respectively, and the concentrations 18 h after administration (C18) were 32 ng/mL and 44 ng/mL, respectively. Therefore, the half-life of remdesivir and GS-441524 was 3.2 and 35.1 h, respectively. Monitoring the plasma concentrations of remdesivir and GS-441524 in patients undergoing ECMO may be necessary.

22 January 2024 in Current Infectious Disease Reports
Verified
Journal Article
Closed access
PDF file
TKToshiyuki Karumai
Toshiyuki Karumai
YKYuki Kotani
Yuki Kotani
RYRyohei Yamamoto
Ryohei Yamamoto
MTMayuko Tonai
Mayuko Tonai
YHYoshiro Hayashi
Yoshiro Hayashi

15 May 2025 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
RYRyohei Yamamoto
Ryohei Yamamoto
HYHajime Yamazaki
Hajime Yamazaki
HNHiroaki Nakagawa
Hiroaki Nakagawa
AOAkihiro Ozaka
Akihiro Ozaka
KHKazuharu Harada
Kazuharu Harada
SFShunichi Fukuhara
Shunichi Fukuhara